Early urinary and plasma biomarkers for experimental diabetic nephropathy

Clinical Laboratory

Volumn 58, Issue 7-8, 2012, Pages 659-671

  Alter, Markus L ^a,b,d   Kretschmer, Axel ^c   Von Websky, Karoline ^a,b   Tsuprykov, Oleg ^a,b   Reichetzeder, Christoph ^a,b   Simon, Alexandra ^a,b   Stasch, Johannes Peter ^e   Hocher, Berthold ^b  

^a DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^b UNIVERSITY OF POTSDAM   (Germany)

^c Bayer HealthCare   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Cardiology Research   (Germany)

Author keywords

Blood biomarker; Clusterin; Diabetic nephropathy; Heart type fatty acid binding protein; Kidney injury molecule 1; Nephrin; Neutrophil gelatinase associated lipocalin; Osteopontin; Tissue inhibitior of metalloproteinases 1; Urinary biomarker

Indexed keywords

ALBUMIN; CALBINDIN; CLUSTERIN; CYSTATIN C; FATTY ACID BINDING PROTEIN; GLUCOSE; KIDNEY INJURY MOLECULE 1; NEPHRIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; PROTEIN H FABP; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLUCOSE BLOOD LEVEL; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RAT; STREPTOZOCIN DIABETES; SURVIVAL RATE; URINARY EXCRETION;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; DIABETIC NEPHROPATHIES; MALE; ORGAN SIZE; RATS; RATS, WISTAR;

ANIMALIA; RATTUS; RATTUS NORVEGICUS; RODENTIA;

EID: 84866083912     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2011.111010     Document Type: Article

References (56)

1. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003;63:1468-74.
2. Ritz E, Schmieder RE, Pollock CA. Renal protection in diabetes: lessons from ONTARGET. Cardiovasc Diabetol 2010;9:60.
3. Ladeia AM, Ladeia-Frota C, Pinho L, Stefanelli E, Adan L. Endothelial dysfunction is correlated with microalbuminuria in children with short-duration type 1 diabetes. Diabetes Care 2005;28:2048-50.
4. Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant 2009;24:1212-9.
5. Liyan C, Jie Z, Xiaozhou H. Prognostic value of combination of heart-type fatty acid-binding protein and ischemia-modified albumin in patients with acute coronary syndromes and normal troponin T values. J Clin Lab Anal 2009;23:14-8.
6. Fukuda Y, Miura S, Zhang B, et al. Significance of urinary liver-fatty acid-binding protein in cardiac catheterization in patients with coronary artery disease. Intern Med 2009;48:1731-7.
7. Nauta FL, Boertien WE, Bakker SJL, et al. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 2011;34:975-81.
8. Pelsers MMAL. Fatty acid-binding protein as marker for renal injury. Scand J Clin Lab Invest Suppl 2008;241:73-7.
9. Endlich N, Sunohara M, Nietfeld W, et al. Analysis of differential gene expression in stretched podocytes: osteopontin enhances adaptation of podocytes to mechanical stress. FASEB J 2002;16:1850-2.
10. Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003;14:S300-4.
11. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. J Clin Invest 1994;94:1597-604.
12. Zhou C, Wu J, Torres L, et al. Blockade of osteopontin inhibits glomerular fibrosis in a model of anti-glomerular basement membrane glomerulonephritis. Am J Nephrol 2010;32:324-31.
13. Yan X, Sano M, Lu L, et al. Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2010;9:70.
14. Rouse RL, Zhang J, Stewart SR, Rosenzweig BA, Espandiari P, Sadrieh NK. Comparative profile of commercially available urinary biomarkers in preclinical drug-induced kidney injury and recovery in rats. Kidney Int 2011;79:1186-97.
15. Aaltonen P, Holthöfer H. The nephrin-based slit diaphragm: new insight into the signaling platform identifies targets for therapy. Nephrol Dial Transplant 2007;22:3408-10.
16. Kestilä M, Lenkkeri U, Männikkö M, et al. Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol Cell 1998;1:575-82.
17. Ruotsalainen V, Ljungberg P, Wartiovaara J, et al. Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc Natl Acad Sci U.S.A. 1999;96:7962-7.
18. Beltcheva O, Martin P, Lenkkeri U, Tryggvason K. Mutation spectrum in the nephrin gene (NPHS1) in congenital nephrotic syndrome. Hum Mutat 2001;17:368-73.
19. Aaltonen P, Luimula P, Aström E, et al. Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy. Lab Invest 2001;81:1185-90.
20. Kelly DJ, Aaltonen P, Cox AJ, et al. Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrol Dial Transplant 2002;17:1327-32.
21. Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993;268:10425-32.
22. Mishra J, Mori K, Ma Q, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2004;15:3073-82.
23. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;365:1231-8.
24. Hirsch R, Dent C, Pfriem H, et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 2007;22:2089-95.
25. Poniatowski B, Malyszko J, Bachorzewska-Gajewska H, Malyszko JS, Dobrzycki S. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in patients with chronic heart failure and coronary artery disease. Kidney Blood Press Res 2009;32:77-80.
26. Nielsen SE, Schjoedt KJ, Astrup AS, et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med 2010;27:1144-50.
27. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006;290:F517-29.
28. Hoffmann D, Fuchs TC, Henzler T, et al. Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity. Toxicology 2010;277:49-58.
29. Dieterle F, Perentes E, Cordier A, et al. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol 2010;28:463-9.
30. Hidaka S, Kränzlin B, Gretz N, Witzgall R. Urinary clusterin levels in the rat correlate with the severity of tubular damage and may help to differentiate between glomerular and tubular injuries. Cell Tissue Res 2002;310:289-96.
31. Ghiggeri GM, Bruschi M, Candiano G, et al. Depletion of clusterin in renal diseases causing nephrotic syndrome. Kidney Int 2002;62:2184-94.
32. Tunçdemir M, Ozturk M. The effects of ACE inhibitor and angiotensin receptor blocker on clusterin and apoptosis in the kidney tissue of streptozotocin-diabetic rats. J Mol Histol 2008;39:605-16.
33. Trougakos IP, Poulakou M, Stathatos M, Chalikia A, Melidonis A, Gonos ES. Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp Gerontol 2002;37:1175-87.
34. Hörstrup JH, Gehrmann M, Schneider B, et al. Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease. Nephrol Dial Transplant 2002;17:1005-13.
35. Kanauchi M, Nishioka H, Nakashima Y, Hashimoto T, Dohi K. Role of tissue inhibitors of metalloproteinase in diabetic nephropathy. Nippon Jinzo Gakkai Shi 1996;38:124-8.
36. Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton) 2007;12:261-6.
37. Hocher B, George I, Diekmann F, et al. ETA receptor blockade induces fibrosis of the clipped kidney in two-kidney-one-clip renovascular hypertensive rats. J Hypertens (Journal of Hypertension) 2000;18:1807-14.
38. Ding S, Qiu C, Hess P, Xi J, Zheng N, Clozel M. Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat. J Cardiovasc Pharmacol 2003;42:48-54.
39. Clozel M, Hess P, Qiu C, Ding S, Rey M. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 2006;316:1115-21.
40. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-30.
41. Susztak K, Böttinger E, Novetsky A, et al. Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes 2004;53:784-94.
42. Nicholas SB, Liu J, Kim J, et al. Critical role for osteopontin in diabetic nephropathy. Kidney Int 2010;77:588-600.
43. Yamaguchi H, Igarashi M, Hirata A, et al. Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients. Endocr J 2004;51:499-504.
44. Fischer JW, Tschöpe C, Reinecke A, Giachelli CM, Unger T. Upregulation of osteopontin expression in renal cortex of streptozotocin-induced diabetic rats is mediated by bradykinin. Diabetes 1998;47:1512-8.
45. Lee C, Lien YH, Lai L, Chen J, Lin C, Chen H. Increased renal calcium and magnesium transporter abundance in streptozotocin-induced diabetes mellitus. Kidney Int 2006;69:1786-91.
46. Toyoda M, Suzuki D, Umezono T et al. Expression of human nephrin mRNA in diabetic nephropathy. Nephrol Dial Transplant 2004;19:380-5.
47. Pätäri A, Forsblom C, Havana M, Taipale H, Groop P, Holthöfer H. Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes 2003;52:2969-74.
48. Elneihoum AM, Falke P, Hedblad B, Lindgärde F, Ohlsson K. Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis 1997;131:79-84.
49. Kuwabara T, Mori K, Mukoyama M, et al. Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int 2009;75:285-94.
50. Timms PM, Wright A, Maxwell P, Campbell S, Dawnay AB, Srikanthan V. Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy. Am J Hypertens 2002;15:269-72.
51. Lindsay MM, Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002;40:136-41.
52. Chaykovska L, Tsuprykov O, Hocher B. Biomarkers for the prediction of mortality and morbility in patients with renal replacement therapy. Clin Lab. 2011;57(7-8):455-67.
53. Hocher B, Ziebig R, Altermann C, Krause R, Asmus G, Richter CM, Slowinski T, Sinha P, Neumayer HH. Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis.. J Am Soc Nephrol. 2003 Sep;14(9):2329-37 54.
54. Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int J Cardiol. 2012 Jan 2. [Epub ahead of print]
55. Chaykovska L, von Websky K, Rahnenfuhrer J, Alter M, Heiden S, Fuchs H, Runge F, Klein T, Hocher B. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One. 2011;6(11):e27861.
56. Vickers SP, Cheetham SC, Birmingham GD, Rowley HL, Headland KR, Dickinson K, Grempler R, Hocher B, Mark M. Klein T, Effects of the DPP-4 Inhibitor, Linagliptin, in Diet-Induced Obese Rats: A Comparison in Naive and Exenatide-Treated Animals. Clin. Lab. 2012;58:787-799.